"AstraZeneca plans major $3.5bn expansion drive in the US" was originally created and published by Investment Monitor, a ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

The jobs include roles in engineering and technical services and global supply chain functions. Read more at straitstimes.com ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...

The group’s shares have tumbled after it emerged that the firm’s China president has been detained as Chinese authorities ...

The decision to pause its investment in Britain came as AstraZeneca announced plans to spend $3.5bn (£2.7bn) expanding its US ...

Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET trial, assessing the ...

At about 23 hectares, the site will mark AstraZeneca’s largest to date in terms of initial build investment. It is targeted to be operationally ready by 2029 to produce antibody drug conjugates (ADCs) ...

AstraZeneca today announces $3.5 billion of capital investment ... the relationship that exists between a patient/site ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

Andrew Berens gave his rating based on several factors, including AstraZeneca’s strong financial performance in the third quarter of 2024. The company reported total revenues of $13.565 billion, ...